Elevation Oncology continually pursues innovations for more efficient and selective drug development in genomically-defined patient populations.
“We’re constantly thinking about how drug development must evolve to keep up with advancements in precision oncology, and are committed to sharing what we learn.”
Shawn Leland, Founder and CEO
We hope that our experiences can inspire and support others embarking on a similar drug development journey.
While each driver alteration may individually be rare, our combined efforts as part of a vibrant precision medicine community can enable a future where every patient’s cancer genomic test results in an actionable treatment decision.